SCTV01C

SCTV01C
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular

SCTV01C is a COVID-19 vaccine candidate developed by Sinocelltech.[1][2][3]

References

  1. ↑ "The Safety and Efficacy of SCTV01C in Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.Healthy Population Aged ≥18 Years Previously Vaccinated With Adenovirus Vectored or mRNA COVID-19 Vaccine". United States National Library of Medicine. 14 September 2021. NCT05043311. Retrieved 14 September 2021.
  2. ↑ "The Safety and Efficacy of SCTV01C in Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine". United States National Library of Medicine. 14 September 2021. NCT05043285. Retrieved 14 September 2021.
  3. ↑ "Safety, Tolerability and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Unvaccinated". United States National Library of Medicine. 8 December 2021. NCT05148091. Retrieved 8 December 2021.


This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.